Indeed, to the best of our knowledge we describe here for the first time a drug-sensitive, genetic-context-dependent BRAF/ERK2/CHOP molecular axis, tightly controlling IL-8 transcription in CRC models. This evidence concerns the gene BRAF and colorectal carcinoma.